Company Snapshot: EMIS  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Emisphere Technologies, Inc. to Webcast Quarterly Earnings Call

    TARRYTOWN, N.Y., Aug. 3 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) will Webcast its quarterly earnings
conference call on Tuesday, August 7, 2007, at 10:00 AM EDT to discuss the
results of its second quarter ended June 30, 2007.
    All interested parties are invited to listen to Emisphere's
President/Chief Executive Officer Michael V. Novinski, and William Rumble,
Corporate Controller, present the quarterly earnings results, highlights
and future direction. Laura Kragie, MD, Vice President of Clinical
Development and Chief Medical Officer, and Lewis H. Bender, Chief
Technology Officer, will also be on the call.
    The live conference call dial-in number is: 1-800-819-9193 (US and
Canada) or 1-913-981-4911 (International). To access a replay of the call,
dial 1-888-203-1112 (US and Canada) or 1-719-457-0820 (International). The
conference replay PIN is 9045496.
    Investors will also have the opportunity to listen to the conference
call over the Internet through Emisphere's Web site at
http://www.emisphere.com. To listen to the live call, please go to the Web
site at least 10 minutes in advance for instructions.
    About Emisphere Technologies, Inc.
    Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules and
pharmaceutical compounds using its eligen(R) technology. These molecules
and compounds could be currently available or are in pre-clinical or
clinical development. Such molecules or compounds usually cannot be
delivered by the oral route of administration or the benefits of these
compounds are limited due to poor bioavailability, slow on-set of action or
variable absorption. The eligen(R) technology can be applied to the oral
route of administration as well other delivery pathways, such as buccal,
per rectum, pulmonary, intra-vaginal or transdermal. The Web site is:
http://www.emisphere.com.


SOURCE Emisphere Technologies, Inc.




Back to Topback to top

Related links:
  • http://www.emisphere.com/
    CONTACT:
    Bob Madison of Emisphere Technologies, Inc.,
    +1-914-593-8360